Palisade Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Palisade Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-1,735	Closed	-$245K	–	571
2016 Q2	$245K	Buy	+1,735	New	+$256K	0.01%	509
2015 Q3	–	Sell	-49,272	Closed	-$8.68M	–	555
2015 Q2	$8.68M	Sell	49,272 -23,507	-32%	-$4.22M	0.22%	170
2015 Q1	$12.6M	Sell	72,779 -32,908	-31%	-$5.65M	0.32%	105
2014 Q4	$17.3M	Buy	105,687 +867	+0.8%	+$144K	0.42%	74
2014 Q3	$16.8M	Buy	+104,820	New	+$16.1M	0.43%	65

Other funds holding JAZZ

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Palisade Capital Management's JAZZ Position: Q3 2016 in Review

Palisade Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2016, closing a stake of 1,735 shares — an estimated $245K sold.

Palisade Capital Management first reported a position in JAZZ in Q3 2014 and held it in 5 quarters. The position peaked at $17.3M in Q4 2014. 325 funds tracked by Wall St. Rank hold JAZZ as of Q3 2016.

Palisade Capital Management reported no remaining Jazz Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Palisade Capital Management sold 1,735 Jazz Pharmaceuticals shares in Q3 2016, an estimated $245K.
Palisade Capital Management first reported a position in Jazz Pharmaceuticals in Q3 2014 and held it in 5 quarters.
Palisade Capital Management's Jazz Pharmaceuticals position peaked at $17.3M in Q4 2014.
325 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2016.

Based on Palisade Capital Management's 13F filing for Q3 2016, filed 8 Nov 2016.